Wednesday, 08 January 2025

Main

Information
Last updated: 29 December 2024 Print

Cerebrotendinous Xanthomatosis (CTX)

Information
Cerebrotendinous XanthomatosisVan Bogaert–Scherer–Epstein syndrome

Introduction

  • Rare autosomal recessive lipid storage disease.
  • Abnormal cholestanol accumulation in the nervous system and other organ systems.
  • Clinical manifestations: Brain, tendons, eyes, arteries.
  • Spectrum of presentations: Infantile diarrhea, cataracts, tendon xanthomas, progressive neurologic impairments.
  • Neurologic manifestations: Ataxia, dystonia, epilepsy, dementia, etc.
  • Diagnostic delay: Median of 16 years.
  • Early intervention with chenodeoxycholic acid (CDCA) critical for prognosis.

Etiology

  • Mutation in CYP27A1 gene encoding sterol 27-hydroxylase.
    • Defective bile acid synthesis → Accumulation of cholestanol.
    • Impacts cholesterol conversion → Multi-organ involvement.

    Epidemiology

    • Rare, underdiagnosed condition.
    • Global prevalence estimates:
      • U.S.: ~1 in 72,000 to 1 in 150,000.
      • Higher prevalence in South Asians and East Asians.

      Histopathology

      • Tendon histology: Foamy histiocytes, multinucleated giant cells, cholesterol clefts.
      • Brain findings: Demyelination, neuronal loss, lipid clefts, reactive astrocytosis.
      • Peripheral nerves: Axonal degeneration.

      Clinical Presentation

      Key Symptoms by Age

      Login to Read More